Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data

Abstract excerpt

BACKGROUND: The antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms that affect 20-30% of people with schizophrenia. Clozapine is markedly underprescribed, partly because of concerns about its narrow therapeutic range and adverse drug reaction profile. Both concerns are linked to drug metabolism, which varies across populations globally and is partly genetically...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Associations and Epidemiology
• Share to Pharmacogenetics and Drug Metabolism
• Share to Schizophrenia research and treatment